AMCP announced the appointment of Mitzi Wasik, PharmD, MBA, BCPS, FAMCP, FCCP, as Executive Director, AMCP Foundation and SVP, Practice Strategy and Innovation, effective September 30.

Welcome to the first Professional Affairs blog! We plan on sharing a periodic post to recap some of the major news, journal articles, reports, and other publications from around the web that have come out since our last post. As this is our first blog, we’ll try to adequately cover the whirlwind that was July and early August 2024.

AMCP CEO Susan Cantrell stresses how collaboration is key in addressing challenges such as high drug prices and healthcare disparities. While there’s no silver bullet, solutions such as tailored population benefit design and value-based contracting can play an important role in making a difference for ordinary Americans looking for affordable access to prescriptions.

Hernandez co-authored a June study in the Journal of Managed Care & Specialty Pharmacy (JMCP) on price benchmarks for selected drugs and their therapeutic alternatives, which concluded different negotiation scenarios for the first 10 drugs. If a drug has a therapeutic alternative, that likely guided the initial price offer from the CMS.

Because most prescription drugs selected for negotiation are highly rebated and discounted—prior to the federal government negotiations—comparisons of MFPs with list prices are somewhat misleading. Many of the ten drugs chosen already had significant rebates, in some cases as high as 68% off of the wholesale acquisition cost.

In this webinar, you'll explore the impact of RSV on U.S. infants, examine key clinical studies on nirsevimab, and review global real-world data on its effectiveness. You'll also learn how to implement immunization strategies to reduce RSV lower respiratory tract infections (LRTI), with practical takeaways for improving coverage and reimbursement decisions.

AMCP recently hosted its third iteration of the IRA workshop series, bringing together health plans, pharmaceutical manufacturers, PBMs, research institutes, and patient advocacy organizations.